An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

Conditions

Breast - Female | Breast - Male | Breast

Phase 1B/2

What is the purpose of this trial?

This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.

  • Trial with
    Deciphera Pharmaceuticals, LLC
  • Start Date
    07/28/2019
  • End Date
    11/10/2020
Trial Image

For more information about this study, contact:

Trisha Burrello

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    08/06/2019
  • Study HIC
    #2000023438